The insulin-like growth factor-I receptor as an oncogene

Haim Werner*, Ilan Bruchim

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

152 Scopus citations


The insulin-like growth factor-I receptor (IGF-IR) mediates the biological actions of both IGF-I and IGF-II. The IGF-IR is expressed in most transformed cells, where it displays potent antiapoptotic, cell-survival, and transforming activities. IGF-IR expression is a fundamental prerequisite for the acquisition of a malignant phenotype, as suggested by the finding that IGF-IR-null cells (derived from IGF-IR knock-out embryos) are unable to undergo transformation when exposed to cellular or viral oncogenes. This review article will focus on the underlying molecular mechanisms that are responsible for the normal, physiological control of IGF-IR gene expression, as well as the cellular pathways that underlie its aberrant expression in cancer. Examples from the clinics will be presented, including a description of how the IGF system is involved in breast, prostate, pediatric, and gynecological cancers. Finally, current attempts to target the IGF-IR as a therapeutic approach will be described.

Original languageEnglish
Pages (from-to)58-71
Number of pages14
JournalArchives of Physiology and Biochemistry
Issue number2
StatePublished - May 2009


FundersFunder number
Insulin-Dependent Diabetes Trust
US–Israel Binational Science Foundation2003341
Israel Cancer Research Fund


    • Cancer
    • Gene expression
    • IGF-I receptor
    • Insulin-like growth factor-I (IGF-I)
    • Targeted therapies


    Dive into the research topics of 'The insulin-like growth factor-I receptor as an oncogene'. Together they form a unique fingerprint.

    Cite this